Patent Application Titled "PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF" Published Online (USPTO 20240318184).

A patent application has been published online discussing the development of iRNA compositions that can inhibit the expression of the PNPLA3 gene, which is associated with nonalcoholic fatty liver disease (NAFLD). The invention aims to provide therapies for individuals suffering from NAFLD, as currently there are no approved pharmacologic treatments for the condition. The patent application describes the specific nucleotide sequences and modifications used in the iRNA compositions, as well as a double-stranded ribonucleic acid (dsRNA) agent that can inhibit the expression of the PNPLA3 gene in cells. Various modifications to the nucleotides in the dsRNA agent are also described to enhance its stability and effectiveness. [Extracted from the article]